Biophan to Detail Breakthrough Nanotechnology Solutions at Lux Executive Summit on the Business of Nanotech; Company CEO to Join Leading Industry and Research Figures at High-Profile Conference on Impact of Nanotechnology.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation medical technology, will be among nanotechnology industry and research leaders at the upcoming Lux Executive Summit, a high-profile national conference focused on the business impact of nanotechnology, being held at the Lux Executive Summit, in the Charles Hotel in Cambridge, MA, October 24-25, 2005.

The conference is being organized by Lux Research, a nanotechnology-oriented research and advisory firm. Expected to attend are Global 1000 corporate leaders, researchers, policymakers and financial leaders who want to understand how nanotechnology will change products, commerce, and ultimately society.

At the conference, CEO Michael Weiner will detail some of Biophan's pioneering nanotechnology-based biomedical applications, including breakthrough solutions to address the $40 billion drug-delivery marketplace, as well as other multi-billion-dollar healthcare industry segments.

"A core component of Biophan's business model and technology portfolio is based upon the creation of business applications of nanotechnology," said Mr. Weiner. "Early on, we recognized the significant potential of nanotechnology to enable truly revolutionary solutions and improvements in healthcare and many other industries."

Biophan has achieved a leadership position in several areas of biomedical technology. The Company initiated its work in the field by developing nanotechnology-based solutions to enable the safe and effective Magnetic Resonance Imaging (MRI) of medical devices and surgical tools. Since then, the Company has progressed into other areas, such as the drug delivery marketplace, for which it is developing advanced solutions in its Nanolution Division.

Biophan's other nanotechnology initiatives include areas such as an implantable bio-thermal power source designed to power and prolong the life of implanted medical devices, such as pacemakers, neurostimulators, and other critical devices. It is co-developing that technology with NASA's Ames Center for Nanotechnology.

Biophan is a biomedical development leader with a strong intellectual property portfolio of 156 U.S. patents, licenses, or applications and 46 international applications.

About Lux Research

Lux Research is the world's leading nanotechnology research and advisory firm. We help our clients make better decisions to profit from nanoscale science and technology, tapping into our analysts' unique expertise and unrivaled network. Our clients include top decision makers at large corporations, portfolio managers and analysts at leading financial institutions, CEOs of the most innovative start-ups, and visionary public policy makers. To get connected and for more information, visit www.luxresearchinc.com. For Lux Executive Summit registration and additional event details, please visit www.luxexecutivesummit.com/Overview/Overview.cfm.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications. This total includes 42 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 106 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. Biophan is also listed on the Frankfurt Stock Exchange under the ticker symbol "BTN." For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.